Daré Bioscience, Inc. (NASDAQ:DARE) Short Interest Up 118.8% in November

Daré Bioscience, Inc. (NASDAQ:DARE) saw a large growth in short interest in November. As of November 30th, there was short interest totalling 55,800 shares, a growth of 118.8% from the November 15th total of 25,500 shares. Based on an average daily trading volume, of 40,500 shares, the short-interest ratio is presently 1.4 days. Approximately 0.7% of the shares of the stock are sold short.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Daré Bioscience in a research note on Friday, November 15th.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Daré Bioscience stock. Renaissance Technologies LLC lifted its stake in shares of Daré Bioscience, Inc. (NASDAQ:DARE) by 2.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 778,700 shares of the biotechnology company’s stock after purchasing an additional 15,800 shares during the quarter. Renaissance Technologies LLC owned about 9.25% of Daré Bioscience worth $262,000 at the end of the most recent reporting period. 6.70% of the stock is owned by institutional investors.

Daré Bioscience Stock Performance

Shares of NASDAQ:DARE opened at $3.18 on Friday. Daré Bioscience has a 52-week low of $3.05 and a 52-week high of $7.56. The company has a market capitalization of $27.67 million, a P/E ratio of -5.38 and a beta of 1.27. The company has a 50-day simple moving average of $3.56 and a 200 day simple moving average of $3.77.

Daré Bioscience Company Profile

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.